Mustafa Iftikhar

Mustafa Iftikhar

Auto-generated profile, based on publicly available information

Mustafa Iftikhar

Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
PCPeter A. Campochiaro
Peter A. Campochiaro
MIMustafa Iftikhar
Mustafa Iftikhar
GHGulnar Hafiz
Gulnar Hafiz
AAAnam Akhlaq
Anam Akhlaq
GTGrace Tsai
Grace Tsai
XKXiangrong Kong
Xiangrong Kong
BACKGROUND. In retinitis pigmentosa (RP), rod photoreceptors degenerate from 1 of many mutations, after which cones are compromised by oxidative stress. N-acetylcysteine (NAC) reduces oxidative damage and increases cone function/survival in RP models. We tested the safety, tolerability, and visual function effects of oral NAC in RP patients. METHODS. Subjects (n = 10 per cohort) received 600 mg (cohort 1), 1200 mg (cohort 2), or 1800 mg (cohort 3) NAC bid for 12 weeks and then tid for 12 weeks. Best-corrected visual acuity (BCVA), macular sensitivity, ellipsoid zone (EZ) width, and aqueous NAC were measured. Linear mixed-effects models were used to estimate the rates of changes during the treatment period. RESULTS. There were 9 drug-related gastrointestinal adverse events that resolved spontaneously or with dose reduction (maximum tolerated dose 1800 mg bid). During the 24-week treatment period, mean BCVA significantly improved at 0.4 (95% CI: 0.2–0.6, P < 0.001), 0.5 (95% CI: 0.3–0.7, P < 0.001), and 0.2 (95% CI: 0.02–0.4, P = 0.03) letters/month in cohorts 1, 2, and 3, respectively. There was no significant improvement in mean sensitivity over time in cohorts 1 and 2, but there was in cohort 3 (0.15 dB/month, 95% CI: 0.04–0.26). There was no significant change in mean EZ width in any cohort. CONCLUSION. Oral NAC is safe and well tolerated in patients with moderately advanced RP and may improve suboptimally functioning macular cones. A randomized, placebo-controlled trial is needed to determine if oral NAC can provide long-term stabilization and/or improvement in visual function in patients with RP. TRIAL REGISTRATION. NCT03063021. FUNDING. Mr. and Mrs. Robert Wallace, Mr. and Mrs. Jonathan Wallace, Rami and Eitan Armon, Marc Sumerlin, Cassandra Hanley, and Nacuity Pharmaceuticals, Inc.

1 January 2019 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
MIMustafa Iftikhar
Mustafa Iftikhar
ALAsad Latif
Asad Latif
UFUmmarah Z. Farid
Ummarah Z. Farid
BUBushra Usmani
Bushra Usmani
JCJoseph K. Canner
Joseph K. Canner
SSSyed M. A. Shah
Syed M. A. Shah
Eye trauma is an important public health problem and one of the most common causes of preventable visual impairment worldwide.1 In the United States alone, an estimated 2.0 to 2.4 million cases of eye trauma occur each year, and nearly 1 million individuals have permanent significant visual impairment because of injury, with more than 75% of these becoming monocularly blind.1-3 In fact, it is estimated that no less than 27% of serious eye injuries in the United States lead to legal blindness (as defined by a visual acuity worse than 20/200).4 Consistently, trauma is considered a leading cause of visual impairment throughout the industrialized world.5-10

1 March 2021 in Ophthalmology
Verified
Journal Article
Closed access
MIMustafa Iftikhar
Mustafa Iftikhar
JCJoseph K. Canner
Joseph K. Canner
LHLeangelo Hall
Leangelo Hall
MAMeleha Ahmad
Meleha Ahmad
DSDivya Srikumaran
Divya Srikumaran
FWFasika A. Woreta
Fasika A. Woreta

10 June 2023 in Ophthalmology
Verified
Journal Article
Closed access
MIMustafa Iftikhar
Mustafa Iftikhar
CDChen Dun
Chen Dun
OSOliver D. Schein
Oliver D. Schein
FLFlora Lum
Flora Lum
FWFasika Woreta
Fasika Woreta

31 January 2019 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
MIMustafa Iftikhar
Mustafa Iftikhar
MLMarili Lemus
Marili Lemus
BUBushra Usmani
Bushra Usmani
PCPeter A Campochiaro
Peter A Campochiaro
JSJosé Alain Sahel
José Alain Sahel
SSSyed Mahmood Ali Shah
Syed Mahmood Ali Shah
Aim To develop a simple and easily applicable classification of disease severity in retinitis pigmentosa (RP). Methods This is a retrospective cross-sectional study. Visual acuity (VA), visual field width (VF) and ellipsoid zone width (EZ) were obtained from medical records of patients with RP. A scoring criterion was developed wherein each variable was assigned a score from 0 to 5 depending on its distribution. The cumulative score (from 0 to 15) was used to classify disease severity from grade 0 to 5. The scores were correlated with each other and the final grade. The grades were then correlated with age and disease duration. Results The median age (range) of patients (n=93) was 55 (12–87) years, 51% were female, 70% had been diagnosed within 10 years, and 50% had autosomal recessive disease. Most eyes (n=181) at least had a VA of 20/40 (67%), a VF of 20° (75%) and an EZ of 5° (76%). All scores were correlated with each other (r=0.509–0.613; p<0.001 for all) and with the final grade (r=0.790–0.869; p<0.001 for all). Except for grade 0 (5%), all grades were evenly distributed: 21% for grade 1, 23% for grade 2, 22% for grade 3, 17% for grade 4 and 12% for grade 5. Grades were correlated with both age (r=0.252; p<0.001) and disease duration (r=0.383; p<0.001). Conclusions We present a simple, objective and easy to use disease severity classification for RP which can be used to categorise and compare patients.

15 December 2018 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
MIMustafa Iftikhar
Mustafa Iftikhar
BUBushra Usmani
Bushra Usmani
ASAbanti Sanyal
Abanti Sanyal
SKSaleema Kherani
Saleema Kherani
SSSimrat Sodhi
Simrat Sodhi
SSSyed M. A. Shah
Syed M. A. Shah